同期放化疗治疗 III 期非小细胞肺癌的有前途的治疗方案：使用数学分析替代常规分割。
The Promising Treatment Schedule of Concurrent Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Alternative for Conventional Fractionation Using Mathematical Analysis.
机构信息
Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan
Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
出版信息
Anticancer Res. 2020 Jul;40(7):4095-4104. doi: 10.21873/anticanres.14408.
BACKGROUND/AIM: To evaluate treatment schedules involving concurrent chemoradiotherapy in stage III non-small cell lung cancer (NSCLC) using the tumor control probability (TCP) and normal tissue complication probability (NTCP) parameters.
PATIENTS AND METHODS
The standard schedules were compared with two types of schedules, the dose escalation and the short-term schedules. Standard schedules were 60-74 Gy in 30-37 fractions. The dose escalation schedules with hypofractionation and hyperfractionation were 69 Gy in 30 fractions and 69.6 Gy in 58 fractions, respectively, twice per day (b.i.d). The short-term schedules were concomitant boost, 64 Gy in 40 fractions b.i.d. and the accelerated radiotherapy schedule, 57.6 Gy in 36 fractions, three fractions per day (t.i.d).
RESULTS
The average TCP for the short-term schedules was more than 16% in two tumor models; however, the TCP for standard and dose escalation schedules was less than 5%. In each organ, the increase in NTCP for the short-term schedule compared with standard schedules was less than 15%.
CONCLUSION
The short-term schedules had an advantage over standard schedules for NSCLC.
背景/目的：利用肿瘤控制概率（TCP）和正常组织并发症概率（NTCP）参数，评估 III 期非小细胞肺癌（NSCLC）中同步放化疗的治疗方案。
患者和方法
将标准方案与两种方案进行比较，即剂量递增和短期方案。标准方案为 30-37 次分割 60-74Gy。每日两次的低分割和超分割剂量递增方案分别为 69Gy/30 次和 69.6Gy/58 次。短期方案为同期加量，64Gy/40 次，每日两次，64Gy/40 次；加速放疗方案为 57.6Gy/36 次，每日三次。
结果
两种肿瘤模型中，短期方案的平均 TCP 均超过 16%；然而，标准和剂量递增方案的 TCP 均低于 5%。在每个器官中，与标准方案相比，短期方案的 NTCP 增加均低于 15%。
结论
对于 NSCLC，短期方案优于标准方案。
Zotero 插件